568 results on '"Angelico P"'
Search Results
352. Successful experience of liver transplantation in maple syrup urine disease (MSUD).
353. Liver transplantation in metabolic diseases: A single center experience.
354. Reply.
355. Compulsory vaccination would exacerbate resistance
356. Reconciling patients’ need for compensation with doctors’ need for protection
357. Exposure and Sensitization to Pets Modify Endotoxin Association with Asthma and Wheeze
358. High prevalence of metabolic syndrome after liver transplantation does not influence long-term survival.
359. Metabolic syndrome and liver transplantation: Incidence and risk factors.
360. Comment on “Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property”.
361. Unexplained hepatic deterioration—Keep in mind hepatitis E virus infection!
362. Author's reply: Comment to “Liver Match, a prospective observational cohort study on liver transplantation in Italy”.
363. Liver stiffness and portal hypertension predict failure to DAA treatment in a real-life cohort of HCV-infected patients treated with recommended regimens.
364. Decreased alpha-fetoprotein levels in HCV cirrhotic patients after direct-acting antiviral agents therapy. Does this indicate a reduced risk of hepatocellular carcinoma?
365. Treatment with direct-acting antiviral agents is associated with improvement of renal function in a cohort of HCV-infected patients with chronic kidney disease.
366. Peer review report 1 on “Ultrasonic versus electrosurgical device for laparoscopic cholecystectomy: A systematic review with meta-analysis and trial sequential analysis”.
367. Visceral fat evaluated by ultrasound is associated with insulin resistance and liver damage in patients with non-alcoholic fatty liver disease.
368. Targeted sequencing of APOC3, GCKR, LIPA, PPP1R3b, NCAN, LYPLAL1 and TM6SF2 genes in patients with nonalcoholic fatty liver disease (NAFLD).
369. Adherence to Mediterranean Diet and non-alcoholic fatty liver disease: Impact on metabolic profile.
370. One year of Editorship: Are we there yet?
371. Costs of hospital bed and chair sensors include the time of healthcare workers monitoring them
372. Excavated pulmonary lesions: differential diagnosis in a health-care worker
373. INDIGO GIRLS ROCKIN' PRIDE.
374. Clinical and functional changes associated with the sustained virological response after treatment of genotype-1 HCV recurrence in liver transplant recipients: Does sofosbuvir differ from peg-interferon based therapy?
375. Treatment failure to first-line direct antiviral (DAA) in HCV-related advanced liver disease: An Italian real-life urban setting.
376. Different prevalence of HCV resistance and HCV quantification within blood and liver samples (tumoral and non tumoral tissues) of HCC/transplanted patients.
377. Sa1498 The Standard-Quality Endoscopy Report: Delphi Consensus to Identify the Hierarchy of Quality Measures.
378. Decreased production of interferon-γ in patients with chronic hepatitis C treated with ribavirin in combination with interferon-alpha
379. Risk factor for early kidney disease after liver transplantation and its impact on graft loss: Insights from the Liver Match cohort study.
380. Transarterial Chemoocclusion (Taco) With Degradable-Starch-Microsphere In Unresecable Hepatocellular Carcinoma: A Prospective Pilot-Study.
381. A hyper-glycosylation of HBV surface major hydrophilic region correlates with immunosuppression-driven HBV reactivation and hampers HBsAg recognition in vitro.
382. OC.04.5 A MODEL TO PREDICT SUCCESS FOLLOWING PEG-INTERFERON AND RIBAVIRIN THERAPY FOR PATIENTS WITH HCV-1 INFECTION.
383. Short-term use of steroids in transplant recipients with recurrent HCV infection is associated with early steatosis and slow progression of hepatic fibrosis
384. Protective role of tauroursodeoxycholate during harvesting and cold storage of human liver a pilot study in transplant recipients. Transplantation 2001; 71 1268.
385. Tauroursodeoxycholate reduces ischemic damage in human allografts: a biochemical and ultrastructural study
386. Recession may decrease mortality trends
387. NOX2-generated oxidative stress is increased in patients with non-alcoholic fatty liver disease independently from metabolic syndrome.
388. HBsAg genetic elements critical for immune escape correlates with HBV reactivation upon immunosuppression.
389. F-49 International benchmarking in liver transplantation in Europe.
390. F-21 PNPLA3 I148M gene variant is not associated with metabolic syndrome and cardiometabolic risk in non-alcoholic fatty liver disease.
391. F-01 Baseline and early dynamic evaluation of HCV NS3-resistance.
392. T-47 Poor predictive ability of the American Donor Risk Index in orthotopic liver transplantation in Europe.
393. T-09 Correlation between NS5A variants and fibrosis progression in patients with HCV recurrence after liver transplantation.
394. OC-24 Genotype analysis, at baseline and early time-points, by population and ultra-deep sequencing in HCV patients treated with BOC/TVR-based therapy.
395. Author reply to comment on “Bleeding and thrombosis in cirrhotic patients: What really matters?”.
396. P.13.15 CHARACTERISTICS, HOSPITALIZATION AND MORTALITY OF PATIENTS WITH GI BLEEDING ADMITTED TO ALL EMERGENCY DEPARTMENTS OF THE LAZIO REGION.
397. P.10.6 RESULTS OF A RETROSPECTIVE SURVEY ON UPPER GASTRO-INTESTINAL BLEEDING IN LAZIO REGION: LARGE VOLUME HOSPITALS EXHIBIT REDUCED MORTALITY BUT AN INCREASED NUMBER OF NEGATIVE ENDOSCOPIC EXAMINATION.
398. P.10.4 RETROSPECTIVE SURVEY ON UPPER GASTRO-INTESTINAL BLEEDING IN LAZIO REGION: COMPARISON BETWEEN URGENT ENDOSCOPY PERFORMED DURING WORKING OR OUT OF WORKING HOURS.
399. Impact of HCV Infection on Graft Survival After Liver Transplantation for Hepatocellular Carcinoma in Compensated Cirrhosis: The Liver Match Cohort Study.
400. P.1.5: POOR ADHERENCE TO PEGYLATED INTERFERON AND RIBAVIRIN IS A MAJOR CONCERN IN THE TREATMENT OF RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION: EVIDENCE FROM THE AISF RECOLT-C STUDY GROUP.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.